This page lists the surgical oncology hospitals in our directory offering Esophageal Cancer Treatment in Mumbai, India, including Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai and others. Each listing links through to the hospital's full profile page.
Ask us about esophageal cancer treatment in Mumbai, India
Share a few details and our care coordination team will get back to you with next steps.
Compare 17 accredited hospitals for Surgical Oncology in Mumbai, India
Featured🇮🇳 Nanavati Super Specialty Hospital
Ranks #1 in this list by listed rating (5/5 from 12 reviews).
🇮🇳 Kokilaben Dhirubhai Ambani Hospital
Ranks #2 in this list by listed rating (4.8/5 from 1800 reviews).
🇮🇳 Tata Memorial Hospital
Ranks #3 in this list by listed rating (4.8/5 from 2500 reviews).
🇮🇳 Apollo Hospitals, Navi Mumbai
Ranks #4 in this list by listed rating (4.8/5 from 512 reviews).
🇮🇳 Gleneagles Hospital, Mumbai
Ranks #5 in this list by listed rating (4.8/5 from 615 reviews).
🇮🇳 Lilavati Hospital And Research Centre
Ranks #6 in this list by listed rating (4.8/5 from 724 reviews).
🇮🇳 Jaslok Hospital
Ranks #7 in this list by listed rating (4.6/5 from 129 reviews).
🇮🇳 Gleneagles Global Hospitals (Global Hospitals)
Ranks #8 in this list by listed rating (4.6/5 from 183 reviews).
🇮🇳 Medicover Hospital, Navi Mumbai
Ranks #9 in this list by listed rating (4.6/5 from 143 reviews).
🇮🇳 KIMS Hospitals, Thane
Ranks #10 in this list by listed rating (4.6/5 from 58 reviews).
🇮🇳 Fortis Hospital, Mulund
Ranks #11 in this list by listed rating (4.5/5 from 79 reviews).
🇮🇳 Fortis Hiranandani Hospital, Vashi
Ranks #12 in this list by listed rating (4.5/5 from 83 reviews).
🇮🇳 Wockhardt Hospital
Ranks #13 in this list by listed rating (4.4/5 from 30 reviews).
🇮🇳 Wockhardt Super Speciality Hospital
Ranks #14 in this list by listed rating (4.4/5 from 48 reviews).
🇮🇳 S. L. Raheja Hospital
Ranks #15 in this list by listed rating (4.4/5 from 121 reviews).
🇮🇳 Saifee Hospital
Ranks #16 in this list by listed rating (4.3/5 from 97 reviews).
🇮🇳 Dr. L H Hiranandani Hospital
Ranks #17 in this list by listed rating (4.3/5 from 141 reviews).
How we selected these hospitals
A hospital appears on this page when Surgical Oncology is among its listed specialties and it is located in Mumbai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Esophageal Cancer Treatment in Mumbai, India?
Choosing the right hospital for esophageal cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include surgical oncology rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Esophageal Cancer Treatment
Esophageal cancer treatment encompasses a multimodal spectrum of interventions — including minimally invasive esophagectomy, chemoradiotherapy, targeted therapy, and immunotherapy — tailored to tumor histology, staging (TNM), and patient performance status. Centers of excellence in India and the UAE report 5-year survival rates of 40–60% for early-stage (Stage I–II) disease and 15–25% for locally advanced (Stage III) disease when treated with curative intent using current protocols. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centers in India and JCI- and DHA-licensed hospitals in Dubai and Abu Dhabi, offering end-to-end coordination from diagnosis confirmation through post-treatment surveillance. Hospital Stay: 10–21 days (varies by modality: surgical resection requires 12–21 days; definitive chemoradiation may require shorter inpatient stays of 5–10 days with outpatient infusion cycles) • Total Stay in Country (Fit-to-Fly): 6–10 weeks after esophagectomy (fit-to-fly clearance requires stable anastomotic healing confirmed by contrast swallow study, adequate nutritional status via jejunostomy or oral intake, and absence of pulmonary complications; chemotherapy-only patients may fly after 2–4 weeks post-cycle) • Success Rate: 40–60% 5-year survival (Stage I–II, curative intent); 15–25% (Stage III with neoadjuvant + surgical protocol)
Clinical Overview
Esophageal cancer is a malignancy arising from the epithelial lining of the esophagus, with two dominant histological subtypes: squamous cell carcinoma (SCC), predominating in the upper and middle thirds and strongly associated with tobacco and alcohol use, and adenocarcinoma (EAC), arising predominantly at the gastroesophageal junction (GEJ) and strongly linked to Barrett's esophagus, chronic gastroesophageal reflux disease (GERD), and obesity. Globally, esophageal cancer ranks as the seventh most common cancer and the sixth leading cause of cancer-related mortality, with an estimated 600,000 new cases annually. The anatomical position of the esophagus — traversing the mediastinum and interfacing with the trachea, aorta, and thoracic duct — makes it a technically demanding site for both diagnosis and resection. Physiologically, tumor obstruction progressively impairs deglutition, leading to dysphagia (initially to solids, then liquids), odynophagia, significant weight loss, malnutrition, and aspiration risk. Advanced disease may involve mediastinal invasion, recurrent laryngeal nerve compromise (causing hoarseness), tracheoesophageal fistula formation, or hematogenous metastasis to the liver, lungs, and bones. Nutritional deterioration directly impacts treatment tolerance, making pre-treatment nutritional optimization — often via nasojejunal tube or percutaneous endoscopic gastrostomy (PEG) — a critical component of the care pathway. The current international standard of care for resectable esophageal cancer is the CROSS protocol (carboplatin + paclitaxel concurrent with 41.4 Gy radiotherapy) followed by surgical resection — an approach demonstrating an R0 resection rate exceeding 92% and a pathological complete response (pCR) rate of approximately 29% in the landmark CROSS trial. For HER2-positive GEJ adenocarcinoma, trastuzumab (Herceptin) combined with platinum-based chemotherapy is standard (ToGA trial data). Immunotherapy with nivolumab (CheckMate 577) is now approved as adjuvant therapy post-resection in patients without pCR, representing a significant paradigm shift. Multidisciplinary tumor board (MDT) review — integrating oncology, thoracic surgery, gastroenterology, radiology, nutrition, and palliative care — is mandatory at accredited centers in both India and the UAE.
Who is a Candidate?
• ELIGIBLE PATIENTS — CURATIVE INTENT: • Histologically confirmed esophageal SCC or adenocarcinoma (biopsy via upper GI endoscopy with EUS-guided sampling) • Clinical staging T1b–T4a, N0–N3, M0 (resectable or borderline resectable disease per AJCC 8th Edition TNM staging) • Eastern Cooperative Oncology Group (ECOG) Performance Status 0–2 • Adequate cardiopulmonary reserve: FEV1 > 1.5 L (or >60% predicted), DLCO > 60%, LVEF ≥ 50% on echocardiography (ECHO) • Adequate hepatic and renal function (bilirubin <1.5× ULN, creatinine clearance >60 mL/min) • Nutritional status permitting: BMI assessment, pre-albumin >15 g/dL, or optimization achievable via enteral support • REQUIRED DIAGNOSTIC WORKUP BEFORE TRAVEL: • Upper GI endoscopy with biopsy (histology, HER2 IHC/FISH for adenocarcinoma) • Endoscopic Ultrasound (EUS) for T and N staging • PET-CT scan (18F-FDG) — whole body, for M-staging and treatment response assessment • High-resolution CT chest/abdomen/pelvis with IV contrast • Pulmonary function tests (PFTs): spirometry and DLCO • 2D Echocardiogram (LVEF assessment prior to anthracycline or trastuzumab use) • Complete blood count, comprehensive metabolic panel, CEA, CA 19-9 (tumor markers) • Laryngoscopy (if SCC with upper-third involvement, to assess vocal cord mobility) • Nutritional assessment by registered dietitian • RELATIVE OR ABSOLUTE CONTRAINDICATIONS: • Distant metastatic disease (M1) — palliative rather than curative protocol applies • Tracheoesophageal fistula (complex surgical planning required; assess case-by-case) • Severe COPD (FEV1 <1.0 L) or oxygen-dependent respiratory failure • Uncontrolled cardiac disease (recent MI within 6 months, uncontrolled arrhythmia, LVEF <40%) • ECOG Performance Status 3–4 (poor tolerance for surgical or chemoradiation protocols) • Active autoimmune disease (relative contraindication for immunotherapy agents) • Cervical esophageal SCC with tracheal/laryngeal invasion (often requires laryngopharyngoesophagectomy — assess at specialized head and neck oncology center)
Treatment Options & Approaches
ENDOSCOPIC RESECTION (Stage T1a/T1b, Early Disease): • Endoscopic Mucosal Resection (EMR): Suitable for flat, superficial lesions confined to the mucosa (<2 cm). Uses submucosal injection and snare resection. Low morbidity, outpatient or short-stay procedure. • Endoscopic Submucosal Dissection (ESD): Preferred for larger en bloc resection of T1a lesions. Provides superior R0 resection margins and intact specimen for histopathological assessment. Requires expert endoscopist; available at tertiary centers in Mumbai, Chennai, Delhi, Dubai, and Abu Dhabi. • Radiofrequency Ablation (RFA): Used for Barrett's esophagus with high-grade dysplasia or residual flat Barrett's post-EMR, to reduce metachronous cancer risk. SURGICAL RESECTION (Stage T1b–T3, Resectable T4a): • Ivor Lewis Esophagectomy (transthoracic, two-field): Right thoracotomy + laparotomy with intrathoracic anastomosis. Gold-standard approach for mid-to-lower esophageal and GEJ tumors. Allows two-field lymphadenectomy (mediastinal + abdominal). • McKeown Esophagectomy (three-stage, three-field): Right thoracotomy + laparotomy + left neck incision with cervical anastomosis. Preferred for upper and mid-esophageal SCC with cervical lymph node involvement. Allows three-field lymphadenectomy. • Transhiatal Esophagectomy (THE): Laparotomy + left neck incision without thoracotomy. Lower pulmonary morbidity; suitable for high-risk pulmonary patients, but limited mediastinal visualization. • Minimally Invasive Esophagectomy (MIE — Thoracoscopic + Laparoscopic): Now the preferred approach at high-volume centers. Meta-analyses confirm significantly reduced pulmonary complications, shorter ICU stay, and equivalent oncological outcomes versus open surgery. Requires laparoscopic gastric conduit formation and thoracoscopic esophageal mobilization. • Robotic-Assisted Minimally Invasive Esophagectomy (RAMIE): Performed with the da Vinci Surgical System (Xi platform). Offers 3D magnification, articulated instrumentation, and tremor filtration — particularly advantageous for precise lymphadenectomy in the paratracheal and subcarinal nodes. Available at AIIMS New Delhi, Tata Memorial Mumbai, Apollo Hospitals, Medanta, Cleveland Clinic Abu Dhabi, and Mediclinic City Hospital Dubai. Studies (TIME trial, ROBOT trial) confirm non-inferior oncological safety and superior short-term surgical outcomes versus open esophagectomy. • Gastric Conduit Reconstruction: Standard conduit for esophageal replacement. Colonic or jejunal interposition used when stomach is unavailable (e.g., prior gastric surgery). CHEMORADIOTHERAPY (Neoadjuvant, Definitive, or Adjuvant): • Neoadjuvant Concurrent Chemoradiotherapy (nCRT) — CROSS Protocol: Carboplatin AUC2 + Paclitaxel 50 mg/m² weekly × 5 weeks, concurrent with 41.4 Gy in 23 fractions. Standard for resectable Stage II–III disease. Achieves pCR in ~29% (SCC) and ~23% (adenocarcinoma). • FLOT Protocol (Perioperative Chemotherapy for GEJ Adenocarcinoma): 5-FU + Leucovorin + Oxaliplatin + Docetaxel — 4 cycles pre-op and 4 cycles post-op. Superior to ECF/ECX regimens (FLOT4 trial). Preferred for resectable GEJ and lower esophageal adenocarcinoma. • Definitive Chemoradiotherapy (dCRT): For cervical esophageal SCC or patients unfit for surgery. 50.4 Gy (conventional fractionation) + concurrent cisplatin/5-FU or carboplatin/paclitaxel. Achieves long-term local control in ~25–30% of SCC patients. • Radiation Technology: Intensity-Modulated Radiation Therapy (IMRT), Volumetric Modulated Arc Therapy (VMAT), and Image-Guided Radiation Therapy (IGRT) are standard at accredited centers, minimizing dose to heart, lungs, and spinal cord. Proton Beam Therapy (PBT) is available at select centers in India (Apollo Proton Cancer Centre, Chennai) for cases with high pulmonary toxicity risk. TARGETED THERAPY & IMMUNOTHERAPY: • HER2-Positive Adenocarcinoma: Trastuzumab (Herceptin) + cisplatin/capecitabine or oxaliplatin-based chemotherapy (ToGA protocol). HER2 IHC/FISH testing mandatory prior to initiation. • Adjuvant Immunotherapy: Nivolumab (Opdivo) — 240 mg IV every 2 weeks or 480 mg every 4 weeks for 1 year — for patients with residual pathological disease (non-pCR) after nCRT + esophagectomy (CheckMate 577 approval). Reduces risk of recurrence by 31% (HR 0.69). • First-Line Metastatic: Nivolumab + chemotherapy (CheckMate 649 for adenocarcinoma; ATTRACTION-3 data for SCC). Pembrolizumab (KEYNOTE-590) for PD-L1 CPS ≥10 tumors. Ramucirumab (anti-VEGFR2) ± paclitaxel for second-line adenocarcinoma. • Molecular Profiling: Comprehensive genomic profiling (CGP via Foundation One CDx or local NGS panels) recommended for all metastatic patients to identify actionable mutations (FGFR2, MET amplification, MSI-H, NTRK fusions). PALLIATIVE & SUPPORTIVE INTERVENTIONS: • Self-Expanding Metal Stent (SEMS) placement for malignant dysphagia palliation • Percutaneous Endoscopic Gastrostomy (PEG) or jejunostomy for enteral nutrition • Palliative radiotherapy for dysphagia, bone metastasis, or superior vena cava syndrome • Best Supportive Care (BSC) with structured palliative care team integration
Recovery
PHASE 1 — PRE-TRAVEL & REMOTE CONSULTATION (Weeks 1–2): • Patient submits medical records (endoscopy report, biopsy histology, CT/PET-CT, PFTs, ECHO, blood work) to GAF Healthcare's medical team. • GAF coordinates a teleconsultation with the treating oncologist and thoracic surgeon at the selected center within 48–72 hours. • Tumor board (MDT) review completed remotely; treatment plan (surgical vs. chemoradiotherapy vs. multimodal) communicated to patient. • Cost estimate, visa invitation letter, and logistics plan issued by GAF Healthcare coordinator. PHASE 2 — ARRIVAL & STAGING CONFIRMATION (Days 1–4 in country): • Airport pickup by GAF-assigned coordinator; accommodation arranged near hospital. • Re-staging workup at destination center (repeat PET-CT if >6 weeks old, EUS if not done, repeat labs, anesthesia pre-assessment, nutritional assessment). • If neoadjuvant chemoradiotherapy is planned (CROSS or FLOT protocol), patient may need to remain 5–6 weeks in country for neoadjuvant treatment before surgery, OR may return home for neoadjuvant treatment locally and return for resection. • Surgical consent, anesthesia review, and optimization (glycemic control, pulmonary physiotherapy, nutritional loading) completed. PHASE 3 — SURGICAL PROCEDURE (Day 5 or Day 1 post-neoadjuvant, Duration: 4–8 hours): • Minimally Invasive Esophagectomy (MIE) or Robotic-Assisted Esophagectomy (RAMIE) performed under general anesthesia with epidural analgesia. • Thoracoscopic phase: esophageal mobilization, systematic mediastinal lymphadenectomy (target: ≥15 nodes per NCCN guidelines). • Laparoscopic phase: gastric conduit fashioning (preserving right gastroepiploic arcade), pyloroplasty or pyloromyotomy, feeding jejunostomy placement. • Anastomosis: intrathoracic (Ivor Lewis) or cervical (McKeown) — performed with circular stapler or hand-sewn technique based on surgeon preference and anatomy. • Intraoperative neuromonitoring for recurrent laryngeal nerve (in three-stage procedures). PHASE 4 — ICU & IMMEDIATE POST-OPERATIVE CARE (Days 1–5 post-surgery): • Admission to thoracic surgical ICU: ventilatory weaning, hemodynamic monitoring, thoracic epidural analgesia management. • Chest drain and nasogastric tube in situ. Jejunostomy feeding commenced at 24 hours post-operatively. • Daily assessment for anastomotic leak (most critical complication: incidence 5–15%), pulmonary complications (pneumonia, ARDS: 15–30%), and chylothorax (thoracic duct injury: 2–4%). • Early mobilization protocol initiated by Day 2. PHASE 5 — WARD RECOVERY (Days 6–14 post-surgery): • Contrast swallow study (Gastrografin) performed Day 5–7 to confirm anastomotic integrity before oral intake. • Progressive oral refeeding: sips of water → semi-liquid diet → soft diet. Jejunostomy feeding continues in parallel. • Removal of chest drains, urinary catheter, and nasogastric tube as clinically appropriate. • Respiratory physiotherapy, incentive spirometry, and ambulation milestones (target: walking 200–400 m by Day 7). • Speech and language therapy assessment for swallowing safety. • Nutritional counseling: high-protein, low-volume, frequent meals; postural guidance (remain upright 30–45 minutes post meals; head elevation 30° at night to prevent reflux and aspiration). PHASE 6 — DISCHARGE & PRE-FLIGHT PERIOD (Days 14–42 post-surgery): • Hospital discharge typically at Days 12–18 post-surgery if all milestones met. • Patient remains at GAF-arranged accommodation near hospital for 3–4 weeks post-discharge. • Follow-up clinic visits at Day 14, Day 21, and Day 42 post-surgery for wound review, drain site check, and nutritional assessment. • Fit-to-fly clearance issued at 6–8 weeks post-esophagectomy: requires confirmed anastomotic healing, stable oral intake, absence of active leak or empyema, and medical review by surgeon. • Business class or premium economy recommended for international flights (semi-reclined posture reduces aspiration risk; avoid pressure on abdominal incision sites). PHASE 7 — POST-DISCHARGE SURVEILLANCE & ADJUVANT THERAPY: • CT chest/abdomen at 3 months post-surgery. • If adjuvant nivolumab indicated (CheckMate 577): 12-month course initiated 4–8 weeks post-surgery — can often be administered at patient's home country oncology center with GAF-provided treatment protocol and records. • Endoscopic surveillance: Upper GI endoscopy at 6 and 12 months post-resection. • 5-year surveillance protocol: CT every 6 months for 2 years, then annually.
Risks to be aware of
Esophageal cancer treatment carries procedure-specific and cumulative risks that patients must understand before undertaking treatment abroad. The most serious surgical complication is anastomotic leak — an incomplete seal at the esophageal-gastric conduit junction — occurring in 5–15% of cases, which may require endoscopic stenting, drainage, or re-intervention and can extend hospitalization by 1–3 weeks. Pulmonary complications (pneumonia, atelectasis, acute respiratory distress syndrome) affect 15–30% of patients post-esophagectomy and represent the leading cause of 30-day post-operative mortality (overall 30-day mortality at high-volume centers: 1–3%). Chylothorax (thoracic duct injury causing lymphatic leak into the pleural cavity) occurs in 2–4% of cases and may require re-operation or pleurodesis. Recurrent laryngeal nerve injury — resulting in vocal cord paresis and hoarseness — occurs in 5–10% of three-stage procedures; most resolve within 3–6 months. Delayed gastric conduit emptying (conduit dysmotility) affects up to 20% of patients and is managed with prokinetics and dietary modification. Chemoradiotherapy carries its own toxicity profile: myelosuppression (nadir at Day 10–14 of each cycle requiring G-CSF support), radiation esophagitis (Grade 2–3 in up to 40% of patients), nephrotoxicity (cisplatin-based regimens), peripheral neuropathy (paclitaxel/oxaliplatin), and immune-related adverse events (irAEs) with PD-1 inhibitors (colitis, pneumonitis, hepatitis — managed with corticosteroid protocols). Nutritional deterioration is a cross-cutting risk: pre-operative malnutrition increases post-operative complication rates by 2–3 fold; all patients should have formal nutritional assessment and optimization prior to surgery. Long-term, patients must adapt to structural changes: smaller stomach capacity (conduit volume ~300–400 mL), altered gastric motility, increased aspiration risk, dumping syndrome (early satiety, vasomotor symptoms post-meals), and bile reflux. Patients traveling internationally for treatment must also account for the risk of delayed access to emergency care during the post-operative period — a primary reason GAF Healthcare mandates a minimum 6-week in-country post-esophagectomy stay before fit-to-fly clearance.
Why GAF Healthcare
GAF Healthcare provides comprehensive end-to-end non-medical coordination for international patients undergoing esophageal cancer treatment in India and the UAE. VISA & DOCUMENTATION — INDIA: • GAF Healthcare assists with the e-Medical Visa (eMV) application for patients traveling to India for treatment. The e-Medical Visa permits a 60-day stay (extendable up to 180 days for prolonged treatment courses) and allows entry of up to 2 attendants on e-Medical Attendant Visas (eMX). GAF provides a hospital invitation letter (mandatory for eMV), treatment cost estimate, and hospital registration documents required by the Indian embassy or High Commission. Processing time: 3–5 business days. Visa fee: approximately USD 25–100 depending on nationality. VISA & DOCUMENTATION — UAE (DUBAI / ABU DHABI): • Citizens of over 50 countries (EU, UK, US, Canada, GCC nationals) receive visa-free or visa-on-arrival entry to the UAE for 30–90 days. For other nationalities, GAF coordinates a medical treatment visa or tourist visa extension through the hospital's international patient services department and UAE Federal Authority for Identity and Citizenship (ICA). DHA (Dubai Health Authority) and DOH (Abu Dhabi Department of Health) medical tourism portals facilitate expedited patient registration. AIRPORT TRANSFERS & IN-CITY TRANSPORT: • Private air-conditioned vehicle pick-up from airport upon arrival, coordinated by the GAF destination coordinator. • All hospital transfers, inter-facility movements (e.g., from diagnostic center to treatment hospital), pharmacy visits, and follow-up appointment transfers are managed by GAF. For post-surgical patients with mobility limitations, wheelchair-accessible vehicles and porter assistance are arranged. DEDICATED PATIENT COORDINATOR & TRANSLATION SERVICES: • Each patient is assigned a dedicated GAF case coordinator (available via WhatsApp, phone, and email, 7 days a week) who liaises between the patient, the hospital's international patient department, insurance companies, and treating physicians. • Professional medical interpreters are available for Arabic, Russian, French, Swahili, Uzbek, and other languages — both in-person at the hospital and remotely via video call during consultations. ACCOMMODATION FOR PATIENTS & ATTENDANTS: • GAF arranges serviced apartments or partner hotels within 1–5 km of the treating hospital, specifically selected for proximity, comfort, and suitability for post-surgical patients (ground floor access, elevator availability, kitchen facilities for dietary preparation). • In India: accommodation options range from budget serviced apartments (USD 30–70/night) to premium hospital guest houses (USD 80–150/night). In the UAE: partner hotel options range from 3-star (USD 80–120/night) to 5-star (USD 200–400/night). • Attendant accommodation is coordinated simultaneously, including options for longer stays during 6–10 week post-esophagectomy recovery periods. INSURANCE & FINANCIAL COORDINATION: • GAF facilitates pre-authorization for international insurance policies and assists with documentation for medical loan or treatment financing applications where applicable. • Itemized cost estimates in USD are provided within 48 hours of receiving medical records, covering surgical, ICU, medication (including biologics/immunotherapy), radiology, and follow-up consultation costs with no hidden fees.
Common questions about Esophageal Cancer Treatment
What is the cost of Esophageal Cancer Treatment in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after esophageal cancer treatment?
What is the success rate of Esophageal Cancer Treatment?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Esophageal Cancer Treatment in Mumbai, India
Discover the Top Hospitals for Esophageal Cancer Treatment in Mumbai, India
This page lists 17 accredited surgical oncology hospitals in Mumbai, India, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about esophageal cancer treatment in Mumbai, India
How many surgical oncology hospitals are listed in Mumbai, India?
How do you choose which hospitals to list?
How much does treatment cost in India?
Are there surgical oncology hospitals for this in other India cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for esophageal cancer treatment in Mumbai, India.
Contact us to report an inaccuracy on this page.